Non-steroidal anti-inflammatory drugs, polygenic risk score and colorectal cancer risk.

Alimentary Pharmacology & Therapeutics
Xuechen ChenHermann Brenner

Abstract

The regular use of non-steroidal anti-inflammatory drugs (NSAIDs) has been associated with reduced colorectal cancer (CRC) risk. To explore whether this association varies according to background polygenic risk for CRC. Data were collected from a large population-based case-control study on CRC in Germany. A polygenic risk score (PRS) based on 140 CRC-related risk loci was used to quantify the genetic risk. The associations of regular use of NSAIDs (≥2times per week for at least 1 year) with CRC risk were estimated in the whole population and in subgroups according to PRS levels using multivariable logistic regression. The impact of NSAIDs on CRC risk was compared to PRS using the 'genetic risk equivalent' (GRE), a recently developed metric for effective risk communication. In total 5129 CRC cases and 4093 controls were included in this analysis. The regular use of NSAIDs (including aspirin) was associated with reduced CRC risk [odds ratio (OR) 0.66, 95% confidence interval (CI) 0.59, 0.74], as was regular use of aspirin only (OR 0.73, 95% CI 0.65, 0.83), without indication of interaction with the PRS (P = 0.10 and 0.22 respectively). The effect of NSAID use was equivalent to the effect of having a 32 percentiles lower PRS (GRE...Continue Reading

References

Sep 7, 1995·The New England Journal of Medicine·E GiovannucciF E Speizer
Aug 15, 1994·Annals of Internal Medicine·E GiovannucciW C Willett
May 15, 2007·Lancet·Enrico FlossmannUNKNOWN British Doctors Aspirin Trial and the UK-TIA Aspirin Trial
Jan 5, 2011·Annals of Internal Medicine·Hermann BrennerMichael Hoffmeister
Jul 25, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hermann BrennerMichael Hoffmeister
Jun 27, 2013·JAMA : the Journal of the American Medical Association·Reiko NishiharaShuji Ogino
Sep 21, 2013·The New England Journal of Medicine·Reiko NishiharaAndrew T Chan
Dec 10, 2013·Journal of the National Cancer Institute·Hongmei NanAndrew T Chan
Dec 3, 2014·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Angel LanasLuis A García-Rodríguez
Mar 18, 2015·JAMA : the Journal of the American Medical Association·Hongmei NanUNKNOWN GECCO
Jun 1, 2015·European Journal of Epidemiology·Peter Kraft, Hugues Aschard
Sep 30, 2016·BMJ : British Medical Journal·Andrea ArfèUNKNOWN Safety of Non-steroidal Anti-inflammatory Drugs (SOS) Project Consortium
Nov 6, 2018·Journal of the National Cancer Institute·Efrat L AmitayMichael Hoffmeister
Mar 15, 2019·International Journal of Cancer. Journal International Du Cancer·Yesilda BalavarcaHermann Brenner
Jul 12, 2019·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Luke McGeochJuliet A Usher-Smith
Sep 30, 2019·Gastroenterology·Bryson W Katona, Jennifer M Weiss
Nov 24, 2019·Gastroenterology·Michael F KaminskiDouglas K Rex
Dec 5, 2019·Clinical and Translational Gastroenterology·Korbinian WeiglHermann Brenner
Apr 3, 2020·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Tian YangEvropi Theodoratou
Aug 8, 2020·American Journal of Human Genetics·Minta ThomasLi Hsu
Mar 2, 2021·Clinical and Translational Gastroenterology·Xuechen ChenHermann Brenner

❮ Previous
Next ❯

Citations

Oct 24, 2021·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Joseph A RothwellNeil Murphy

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.